E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Onychomycosis (OM) is a chronic fungal infection of the finger- or toenails and one of the commonest dermatological conditions. It accounts for one third of fungal skin infections and constitutes about a half of all nail abnormalities. In most cases, OM is caused by dermatophytes, mostly Trichophyton rubrum (84-90%). Yeasts (e.g. Candida parapsilosis; approx. 8 %) or moulds like Scopulariopsis brevicaulis (approx. 6%) are other common causative organisms of OM.
|
|
E.1.1.1 | Medical condition in easily understood language |
Onychomycosis is a chronic fungal infection of the finger- or toenails. It is one of the most frequent diseases of the body surface. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Bacterial Infections and Mycoses [C01] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluation of the clinical efficacy of PD P 506 A photodynamic therapy of DSO of the great toenail(s) on nail basis 12 months after treating participants. |
|
E.2.2 | Secondary objectives of the trial |
• Evaluation of the efficacy of PD P 506 A photodynamic therapy of DSO of the great toenail(s) on nail basis 12 months after treating participants as measured by laboratory methods. • Evaluation of the efficacy of PD P 506 A photodynamic therapy of DSO of the great toenail(s) on nail basis 3 and 6 months after treating participants. • Evaluation of safety and tolerability of PD P 506 A photodynamic therapy of DSO of the great toenail(s).
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Male patients, 18 - 75 years of age • Females up to an age of 75 years, provided that they are postmenopausal, i.e. with spontaneous amenorrhea for at least 12 months or not of childbearing potential because of tubal ligation or hysterectomy • DSO of at least one of the great toe(s) affecting 20% to 60% of the target nail without spikes will be confirmed by at least one of the three methods: the methods of KOH test, periodic acid-Schiff (PAS) stain and mycology culture • The toenail infection can be due to a dermatophyte, yeast or mixed infections (dermatophyte and non-dermatophyte) • Toenails have to be cut regularly (indicator for existing growth) • Signed written informed consent
|
|
E.4 | Principal exclusion criteria |
• Patients with the target toenail involving the matrix (lunula) or having less than 2 mm clear (unaffected) nail plate length beyond the proximal fold • Presence of dermatophytoma (defined as demarcated and localised thick masses (≥ 3 mm) of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail • Other conditions than DSO known to cause abnormal nail appearance • Topical antifungal treatment of the nails within 1 month before PDT • Systemic use of antifungal treatment within 3 months before PDT • Patients who are unwilling to provide nail clippings • Patients who have been previously reported to be allergic against 5-aminolevulinic acid or other ingredients of PD P 506 A • Diagnosis of porphyria • Diagnosis of polyneuropathy • Dementia or psychic condition that might interfere with the ability to understand the study and thus give written informed consent • Simultaneous participation in another clinical study or participation in another clinical study in the 30 days directly preceding treatment
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Percentage of nails with Clinically Complete Cure (CCR; clinically complete clear nail). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
12 months after the last study treatment |
|
E.5.2 | Secondary end point(s) |
• Photo documentation. • Percentage of nails with negative result after 12 months using laboratory methods (KOH test, periodic acid-Schiff (PAS) stain and mycology culture). • Percentage of nails with CCR after 3 and 6 months of treatment. • Frequency and severity of adverse events and local tolerability signs/symptoms.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
3, 6 and 12 months of treatment (see above). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |